FDAnews
www.fdanews.com/articles/84556-new-osteoarthritis-therapy-approved-in-the-eu

NEW OSTEOARTHRITIS THERAPY APPROVED IN THE EU

February 14, 2006

After the successful completion of clinical studies, the German biotech company Orthogen AG (Dusseldorf) intends to build up a Europe-wide distribution of Orthokine(R). Orthokine(R) is a medical device for the production of autologous conditioned serum; containing anti-inflammatory cytokine antagonists and growth factors.Two universities performed randomized double-blind studies demonstrating its high efficacy and safety in the therapy of osteoarthritis of the knee and low back pain.

Presseportal (http://www.presseportal.de/story.htx?nr=785610)